Socium is AI-driven drug discovery biotech predicts the correlation between drugs and diseases based on gene expression. Our innovative AI platform is capable of finding new additional indications for YOUR compound in clinical phase 2 or 3. Especially orphan disease and intractable diseases including cancers.
In addition, the company currently has a development portfolio of over 23 diseases, including oncology and rare diseases. The company replaces multiple steps in the traditional drug discovery process with an in-silico system using our cutting edge algorithm, established a system to identify the drug discovery target in a few months.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 2-4-7, Aomi, Aist Tokyo Waterfront Bio-It Research Building,japan
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- socium.co.jp
- Keywords
- Rare Disease, Artificial Intelligence, Drug Discovery, Oncology, Unmet Medical Needs, Orphan, Biotech.
- HQ
- Koto-ku, Tokyo
Socium Inc. Questions
Socium Inc.'s website is socium.co.jp
Socium Inc.'s LinkedIn profile is https://jp.linkedin.com/company/socium-inc
Socium Inc. has
6 employees.
View email and phone details for 6
employees at Socium Inc..
Socium Inc.'s industry is
Biotechnology Research
Socium Inc.'s top competitors are
Celltech Accelerator,
Shuimu Biosciences,
Umn Pharmacology,
Knowledge Palette, Inc.,
Sk Kaken Co Ltd,
Molcure Inc.,
Epigno Corporation,
Chordia Therapeutics Inc,
Peptidream Inc.,
Luca Science Inc..
Socium Inc.'s categories are Biotechnology Research
Socium Inc.'s founding year is 2017
